Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication

Walter W. Hong, Ihor W. Rak*, Vincent T. Ciuryla, Anastasia M. Wilson, Jelle W. Kylstra, Herbert Y. Meltzer, William T. Carpenter, Anthony Lehman, Lisa A. Arvanitis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Treating schizophrenia is expensive. Preventing rehospitalization of patients with schizophrenia provides an attractive opportunity for cost savings, especially for patients with 'revolving-door' or multiple-episode schizophrenia. Reducing the occurrence of extrapyramidal symptoms and other adverse events associated with standard antipsychotic agents may increase compliance and reduce the rate of rehospitalization of patients with schizophrenia. Quetiapine ('Seroquel', ICI204,636, Zeneca Pharmaceuticals) is a new dibenzothiazepine antipsychotic agent with a low propensity for extrapyramidal symptoms. We describe here a unique methodology to compare quetiapine with usual-care medications in real-world treatment settings. The trial objective is to determine if therapy with this new atypical antipsychotic agent can reduce the rate of rehospitalization and, therefore, treatment costs. Using two secondary medical-claims databases, we defined the minimal threshold for revolving-door status as 1.0 admission per year; this definition allows our trial to focus on the subpopulation of schizophrenic patients with the greatest potential for cost savings by either the new atypical antipsychotic quetiapine or usual-care therapy. We describe here the approach used in our trial.

Original languageEnglish (US)
Pages (from-to)51-58
Number of pages8
JournalSchizophrenia Research
Issue number1
StatePublished - Jun 22 1998


  • Drug costs
  • Drug effects
  • Extrapyramidal tracts
  • Healthcare costs
  • Quetiapine
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication'. Together they form a unique fingerprint.

Cite this